Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Best Pharma Stocks With Buy/ Hold Recommendation



Daljeet Kohli and his team at IndiaNivesh have conducted a comprehensive preview of the Q2FY15E Results of the best pharma stocks and given buy/ hold recommendations




The report explains in detail the expectations of each stock and what its prospects will be in the near future. Thereafter, the report also gives the target price of each stock and provides for a buy or hold recommendation.

All the top-quality stocks, namely, Ajanta Pharma, Alembic Pharma, Aurobindo Pharma, Biocon, Cadila, Cipla, Divis Lab, Dr Reddy, Glenmark, Ipca Lab, JB Chemicals, Jubilant LifeSciences, Lupin, Sharon Bio‐medicine, Shilpa Medicare, Sun Pharma and Torrent are covered in the report.

Click here to download Q2FY15E Results Preview Of Pharma Sector By IndiaNivesh
investments, Large Cap, Mid Cap, Multibagger, Portfolio, Top Picks    , , , , , , ,

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!